UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.15 ^USD	+2.39%		+3.06%	-5.67%

Apr. 15	UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	MT
Apr. 03	UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	MT

UroGen Pharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 08:05 am EDT

UroGen Pharma Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 21.14 million compared to USD 16.6 million a year ago. Net loss was USD 24.14 million compared to USD 26.69 million a year ago. Basic loss per share from continuing operations was USD 1.03 compared to USD 1.18 a year ago.
For the six months, sales was USD 38.33 million compared to USD 30.17 million a year ago. Net loss was USD 54.35 million compared to USD 55.08 million a year ago. Basic loss per share from continuing operations was USD 2.33 compared to USD 2.43 a year ago.

Latest news about UroGen Pharma Ltd.

UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	Apr. 15	MT
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	Apr. 03	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $34 From $35, Maintains Outperform Rating	Mar. 15	MT
Transcript : UroGen Pharma Ltd., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
UroGen Pharma Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
UroGen Pharma Starts Rolling NDA Submission for Bladder Cancer Drug	Jan. 24	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $32, Maintains Outperform Rating	Jan. 24	MT
UroGen Pharma Ltd. Initiates Submission of a Rolling NDA to the FDA for UGN-102	Jan. 24	CI
Urogen Pharma Ltd. Enters into A License and Supply Agreement (The Agreement) with Medac Gesellschaft Für Klinische Spezialpräparate m.b.H	Jan. 17	CI
UroGen Pharma Ltd. Plans to Initiate Phase 3 Study in 2024	Jan. 17	CI
UroGen Signs Licensing Deal With Medac to Develop New Formulation for Urothelial Cancer; Shares Rise	Jan. 17	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $32 From $33, Maintains Outperform Rating	Nov. 15	MT
Transcript : UroGen Pharma Ltd., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (URGN) UROGEN PHARMA Reports Q3 Revenue $20.9M, vs. Street Est of $20M	Nov. 14	MT
UroGen Pharma Ltd. Reiterates Revenue Guidance for the Full Year 2023	Nov. 14	CI
North American Morning Briefing : Caution -2-	Nov. 14	DJ
Transcript : UroGen Pharma Ltd., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
UroGen Pharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (URGN) UROGEN PHARMA Posts Q2 Revenue $21.1M, vs. Street Est of $20.1M	23-08-10	MT
UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023	23-08-10	CI
HC Wainwright Adjusts Price Target on UroGen Pharma to $54 From $23, Maintains Buy Rating	23-08-01	MT
Goldman Sachs Adjusts UroGen Pharma Price Target to $18 From $11, Maintains Neutral Rating	23-07-31	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $33 From $22, Maintains Outperform Rating	23-07-28	MT

Chart UroGen Pharma Ltd.

Duration

Period

More charts

Company Profile

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - AUA Innovation Nexus Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for UroGen Pharma Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.15 USD

Average target price

38.5 USD

Spread / Average Target

+172.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
UROGEN PHARMA LTD.	-5.67%	483M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs